One Rockefeller Plaza
About Hoth TherapeuticsHoth Therapeutics Inc. is a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis.
CEO: Robb Knie
185 articles about Hoth Therapeutics
A summary of IPOs from companies in the biotech and pharma world since Oct. 1, 2018.
Hoth Therapeutics Inc. Announces Completion of Series A Financing
Hoth Therapeutics Inc. ("Hoth" or the "Company"), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema, announced today that it has completed its Series A financing totaling $3 million, before expenses, to fund operations and advance Hoth's BioLexa Platform.
Hoth Therapeutics Announces Issuance of First U.S. Patent on its BioLexa Platform
The new patent is part of the technology portfolio Hoth is developing under an exclusive license from the UC.
Hoth Therapeutics Announces The Addition Of Dr. Richard D Granstein, M.D. To The Company's Technology Advisory Board
Hoth Therapeutics announced today the addition of Dr. Richard D. Granstein, M.D., to the Company's Technology Advisory Board.
Hoth Therapeutics Announces The Addition Of Dr. Andrew Herr To The Company's Technology Advisory Board